• Home  
  • Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
- Health

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

Competing interests B.G. reports personal fees from Ipsen, Foundation Medicine, Boston Scientific, Astellas Pharma and Amgen; grants and personal fees from Taiho Oncology, Roche/Genentech, AstraZeneca and Pfizer; and grants from Hoffman La-Roche, Toray, Hutchison MediPharma, Mirati Therapeutics, CARsgen Therapeutics, GlycoNex, Helix Biopharma, Tvardi Therapeutics, Transcenta, BioNTech, Legend Biotech, Elicio Therapeutics and Obsidian. H.S. reports honoraria

Competing interests

B.G. reports personal fees from Ipsen, Foundation Medicine, Boston Scientific, Astellas Pharma and Amgen; grants and personal fees from Taiho Oncology, Roche/Genentech, AstraZeneca and Pfizer; and grants from Hoffman La-Roche, Toray, Hutchison MediPharma, Mirati Therapeutics, CARsgen Therapeutics, GlycoNex, Helix Biopharma, Tvardi Therapeutics, Transcenta, BioNTech, Legend Biotech, Elicio Therapeutics and Obsidian. H.S. reports honoraria from UpToDate; consulting or advisory roles from Merck, Dewpoint Therapeutics and Zola Therapeutics; speakers’ bureau with PeerDirect; research funding from Elicio Therapeutics, AstraZeneca and Daiichi Sankyo; and travel, accommodations and expenses from Dava Oncology. C.E.D. reports honoraria from Vivacitas; consultancy/advisory board relationship with Pfizer; and research funding (to institution) from Elicio Therapeutics. V.C. has held consulting or advisory roles at Immuneering, Ispen, Gristone Oncology, Westwood Bioscience, Perthera and Apeiron Biologics. He has been on the speakers’ bureau for Ipsen and Celgene. He has received research funding (to institution) from Elicio Therapeutics, Roche and Merck. A.H. is a consultant for Novartis, Ipsen, Valar Labs, PANCAN, Faraday Pharmaceuticals, Amgen, Regeneron, Exelexis, Alcresta Therapeutics, Pfizer, Curium Pharma and Merck; has received research funding from Ipsen; institutional research funding from NGM Biopharmaceuticals and Elicio Therapeutics; travel fees from Halozyme; and other compensation from RayzeBio. P.J.H. has held consulting or advisory roles at Fibrogen, Betaglue Therapeutics, Revolution Medicines, and Elicio Therapeutics (Scientific Advisory Board/stock ownership). He has received research funding (to institution) from Elicio Therapeutics. D.W.K. reports grants or contracts from Bold Therapeutics, research funding (to institution) from Elicio Therapeutics, and payment or honoraria from AstraZeneca. J.B.V. reports research funding (to institution) from Elicio Therapeutics, and Honoraria from AstraZeneca. T.B.-S. reports research funding (to institution) from Elicio Therapeutics, Amgen, Ipsen, Lilly, Bayer, Roche/Genentech, AbbVie, Incyte, Immuneering, Seagen, Pfizer, Boehringer Ingelheim, Janssen, Eisai, Daiichi Sankyo/UCB Japan, AstraZeneca, Exact Sciences, Natera, Treos Bio, Celularity, Sobi, BeiGene, Foundation Medicine, Arcus Biosciences, Stemline Therapeutics, Kanaph Therapeutics, Deciphera, Illumina, Caladrius Biosciences and Zai Lab. Other relationships: Exelixis, Merck (Inst), AstraZeneca, Lilly, Pancreatic Cancer Action Network, FibroGen, Suzhou Kintor Pharmaceuticals, 1Globe Health Institute, Imugene, Xilis, Replimune, Sun Biopharma and UpToDate. D.B.C. reports consulting fees from Sago Pharma and the KOL Connection; grant and/or research funding to institution from Elicio Therapeutics, Novartis, XBiotech, Elicio and Arcus Biosciences; and travel reimbursement from Arcus Biosciences. M.H. reports research funding (to institution) from Elicio Therapeutics; other support from Bristol-Myers Squibb and Nelum; personal fees and other support from Champions Oncology, InxMed and OncoMatrix; and personal fees from MiNKi and Peaches outside the submitted work, as well as being a member of the Bristol-Myers Squibb board of directors. P.M.K. reports consultancy/advisory board relationships with Elicio (Scientific Advisory Board Member/Stock Ownership), Founder, Percision BioSensors; consultancy/advisory board relationships with Agenus, Astellas, AstraZeneca, Beixon, Elicio Therapeutics, Guardant Health, Illumina, Natera, Foundation Medicine, Daichi Sankyo, Tempus, Bayer, MSD Oncology/Merck, Neogenomics, Delcath Systems, QED, Taiho Oncology (self/institution), Exact Sciences, Eisai, BostonGene, Neogenomics, Saga Diagnostics, Regeneron, Servier, Seagen, Lilly, Xilio Therapeutics and Ipsen (to institution); and research funding/trial support from Merck (to institution), Novartis (to institution), and Agenus Bio (to institution). A.D.L. reports honoraria from MedPro Specialty Advisory Board; institutional contracts with Elicio Therapeutics, Bristol-Myers Squibb, Exelixis, FameWave, Antengene, Arrys Therapeutics, Hutchison Medipharma, Corcept Therapeutics, Conjupro Biotherapeutics, Takeda, Boehringer Ingelheim Pharmaceuticals, Johnson & Johnson, AbbVie and Bayer U.S. for trials where she is the local principal investigator. She served as Pancreatic Cancer/Neuroendocrine Co-Chair on the Elsevier ClinicalPath Oncology Committee during the course of this clinical trial. M.P. reports research funding (to institution) from Arcus Biosciences, Astellas Pharma, Codiak Biosciences, CytomX, Eisai, Elicio Therapeutics, Gritstone, HiberCell, Immune-Onc Therapeutics, OncXerna Therapeutics, SQZ Biotechnologies, Surface Oncology, TransThera Sciences and ZielBio. N.F. reports research funding (to institution) from Elicio Therapeutics. C.D.W. reports research funding from Elicio Therapeutics, Novartis, Actuate Therapeutics, Merck, AstraZeneca, Dicephera Pharmaceuticals, Genentech/Roche and Mirati. Advisory board relationships with Ipsen, Celgene, Novartis, Merrimack, Actuate Therapeutics and Genentech. M.H.O. reports research funding (to institution) from Bristol-Myers Squibb, Celldex, Elicio, Revolution Medicine, Verastem, Genentech, Merck, Persevere, Parabalis, Jazz, Incyte, AstraZeneca and Arcus; grants and nonfinancial support from Stand Up To Cancer, Lustgarten Foundation; and advisory board fees from Natera, Revolution Medicine and Verastem. T.J.G. reports DSMB membership for Pfizer, Nihon Medi-Physics, KAHR Medical and Arbele; consultant/advisory fees from Avammune Therapeutics, BillionToOne, Exact Sciences, Summit Therapeutics, Janssen Oncology, Pfizer and Genentech; research funding (to institution) from Bristol-Myers Squibb, Merck, AstraZeneca, Lilly, Bayer, Incyte, Ipsen, Genentech, Astellas Pharma, GlaxoSmithKline, Amgen, OncoC4, BillionToOne, Jounce Therapeutics, Elicio Therapeutics, AMAL Therapeutics/Boehringer Ingelheim, Seagen, Regeneron and Deciphera. S.M.K. reports research funding (to institution) from Elicio Therapeutics and Johnson & Johnson. J.D.M. reports research funding (to institution) from Elicio Therapeutics; honoraria from Exelixis and AstraZeneca; consulting or advisory fees from Exelixis, Daichii Sankyo, Seagen and Amgen; and speakers’ bureau participation from Exelixis, AstraZeneca and Bristol-Myers Squibb Foundation. S.N. reports research funding (to institution) from Bristol-Myers Squibb, Mirati Therapeutics, Strata Oncology, Elicio Therapeutics, Merck and Iovance. M.M. reports no conflicts of interest. T.K. reports consulting and stock ownership from Elicio Therapeutics. G.A. and J.X. report consulting from Elicio Therapeutics. J.P.S., M.H.M., X.C.-P., J.R.P., L.K.M., E.W., P.C.D. and C.M.H. are employees of Elicio Therapeutics and, as such, receive salary and benefits, including stock ownership. L.K.M., P.C.D. and C.M.H. have amphiphile vaccine patents pending: (patent number 12,138,301 (United Arab Emirates, Brazil, Canada, China, Hong Kong, India, Japan, South Korea, Mexico, Nigeria, Thailand, USA, South Africa) and patent number 12,247,052 (United Arab Emirates, Brazil, Canada, China, India, Japan, South Korea, Thailand, USA, South Africa)) to Elicio Therapeutics. S.P. reports research funding (to institution) from Amal Therapeutics, Arqule, Bristol-Myers Squibb, Eli Lilly, Elicio Therapeutics, Holy Stone Healthcare, Immuneering, ImmunoMET, Ipsen, Lilly, Mirati Therapeutics, Novartis, Purple Biotech, Rgenix, Sanofi-Aventis, Xencor, Astellas, Framewave, 4D Pharma, Boehringer Ingelheim, NGM Biopharmaceuticals, Janssen, Arcus Biosciences, Biontech, Zymeworks and Pfizer. Financial relationship consultant/advisory fees from: Alligator Bioscience, Askgene Pharma, AstraZeneca, BPGBio, Zymeworks, Ipsen, Nihon Medi-Physics, Novartis, Janssen, Jazz Pharmaceuticals, US WorldMeds and Boehringer Ingelheim. Z.A.W. reports consultant/advisory fees from Alligator Bioscience, Bayer, Lilly Oncology, AstraZeneca, Merck, Merck KGaA, Daiichi Sankyo, Macrogenics, Amgen, Bristol-Myers Squibb, Astellas, Ipsen, Arcus, Novartis, PureTech, Roche, Seagen and Pfizer; and received research funding (institutional) from Elicio Therapeutics, Five Prime Therapeutics, Arcus, Pfizer, Plexxikon, Novartis and Merck. E.M.O. reports Genentech/Roche, BioNTech, Bristol-Myers Squibb, AstraZeneca, Arcus, Elicio Therapeutics, Helsinn Healthcare, Parker Institute, NIH/NCI, Puma Biotechnology, Digestive Care, Break Through Cancer, Agenus, Amgen, Revolution Medicines, QED, Yiviva (research funding to institution), Abbvie, Arcus, AstraZeneca, Autem Medical, Ability Pharma, Alligator BioSciences, Agenus, Berry Genomics, BioNTech SE, Boehringer Ingelheim, Ipsen, Ikena, Merck, Moma Therapeutics, Novartis, Leap Therapeutics, Astellas, Bristol Meyers Squibb, Revolution Medicines, Regeneron, Tango (consulting/DSMB), Thetis Pharma (uncompensated relationship), BioNTech, Arcus (travel) and AbbVie (spouse).

Source: www.nature.com

About Us

Toolq Media Is a Global News Platform Covering the Latest Developments and Breaking Stories from Around The World, Including World News, Business, Finance, Technology, Health, Politics, Science, Entertainment, Sports, and More.

Toolq

Toolq @2026. All Rights Reserved.